Meningococcal A, C, Y and W‐135 polysaccharide‐protein conjugate vaccines

AUTOR(ES)

Pace, David

FONTE

BMJ Group

RESUMO

Serogroup C meningococcal conjugate vaccines, first launched in the UK in 1999, have been used successfully in Australia, Canada and several other European countries. Combination conjugate vaccines, containing more than one meningococcal polysaccharide, have been developed to broaden protection against the disease. A tetravalent meningococcal A, C, Y and W‐135 conjugate vaccine was licensed for use in 11–55 year old adolescents and adults in the US in January 2005, and subsequently also in 2–11 year old children in Canada in May 2006. This article discusses the different glycoconjugate meningococcal vaccines which have been developed and the potential for their use to control disease caused by serogroups A, C, Y and W‐135 of Neisseria meningitidis.

Documentos Relacionados

• Assignment of Additional Anticapsular Antibody Concentrations to the Neisseria meningitidis Group A, C, Y, and W-135 Meningococcal Standard Reference Serum CDC1992
• Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines.
• Safety and Immunogenicity of Improved Shigella O-Specific Polysaccharide-Protein Conjugate Vaccines in Adults in Israel
• Development and Evaluation of a Tetraplex Flow Cytometric Assay for Quantitation of Serum Antibodies to Neisseria meningitidis Serogroups A, C, Y, and W-135
• Capsular polysaccharide-protein conjugate vaccines of carbotype 1 Vibrio vulnificus: construction, immunogenicity, and protective efficacy in a murine model.